# A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis

> **NCT00077870** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 237 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** ocrelizumab

## Key facts

- **NCT ID:** NCT00077870
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 237 (—)
- **Last updated:** 2009-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077870, "A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00077870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*